Tevogen Bio Holdings Inc (TVGN) Stock Price, Quote & News

Company Profile

Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a...

Industry: Biotechnology

Sector: Healthcare

Phone: 877 838 6436

Website: tevogen.com

Address:

15 Independence Boulevard, Suite #210, Warren, United States

mat70 Sep. 2 at 2:50 PM

$TVGN 2/2 The primary milestones that need to be met, ideally before EOY, would be closure of their LOI acquisition targets without significant shareholder dilution. That would provide immediate revenue to fund a) ongoing operations, and b) at least part or all of the next phase for TVGN-489. Second, they need to secure and productionize their manufacturing facility. If these milestones are hit, then in my opinion, it warrants a significant re-rating of the company's risk profile. This is a good test of management's ability to execute. If not, then further skepticism is warranted and the investment thesis begins to buckle. We shall see how things play out.

1 · Reply

mat70 Sep. 2 at 2:49 PM

$TVGN @robsmi63 1/2 Skepticism is warranted; scam is hyperbole. Yes, the communications are muddled particularly with the press release strategy, but the fundamentals remain intact for a reasonable investment thesis. The risk is high, as with any clinical stage biotech. FDA approvals take time. They don't happen overnight and there are other pieces to the puzzle that need to fall into place first. They already received Phase 1 IND clearance with TVGN-489, and by any measure, the trial was highly successful. Granted future trials will be more rigorous but that does lend to the credence of their tech and leading candidate. The executive team has decades of expertise and credibility in the field. There is no evidence they are charlatans. 1/2

3 · Reply

robsmi63 Sep. 2 at 11:29 AM

$TVGN and yes Saadi Scam, I've nothing better to do then expose your Scam.

0 · Reply

robsmi63 Sep. 2 at 11:28 AM

$TVGN is a Scam. They've regurgitated their bullshit for three years. Their product isn't through FDA because it's obviously part of their scam. How about wait until FDA approvals before investing in this scam? Just saying.

0 · Reply

Nikniko55 Aug. 31 at 8:34 PM

$TVGN news?

1 · Reply

NGCS Aug. 28 at 4:56 PM

$TVGN Seen CV of management, I think this is a serious team and project; of course everything could work faster and better, but sincerely they have successfull experiences in Wall Street and big with some blockbusters (you can check in on internet). I didnot talk about Patel Family, but they made billions usd in Medical and Pharmas. So now it is time for this company IMO. NFA. Best regards

0 · Reply

NGCS Aug. 28 at 4:49 PM

$TVGN The Financial: Manjit Singh (CFO) 💼 • 20+ years executing M&A, capital allocation & global finance at Novartis & Sanofi. • Master of complex corporate structuring, licensing deals & balance sheet management. • Key driver in commercializing multi-billion dollar pharma portfolios. The exact heavyweight financial execution needed to close the MSO/CRO deal and scale revenue. 📈💰 #Biotech #StockTwits

0 · Reply

NGCS Aug. 28 at 4:48 PM

$TVGN The Brains Behind the Tech: Dr. Neal Flomenberg (CSO) 🔬 • Pioneer in cell therapy & bone marrow transplants from Memorial Sloan Kettering (MSKCC) & Jefferson Health. • Decades of FDA-level clinical innovation building off-the-shelf T-cell immunotherapies. • World-class scientific authority backing $TVGN’s proprietary platform (TVGN-489). Institutional-grade science leading the charge. 🧠💥 #Biotech #Tcell #StockTwits

0 · Reply

NGCS Aug. 28 at 4:47 PM

$TVGN Meet the CEO behind the strategy: Dr. Ryan Saadi 🧬: • Ex-Senior Leader at Johnson & Johnson, Sanofi & Genzyme (Yale MPH / MD). • Key driver in commercializing $1B+ blockbuster therapies like Aubagio® & Lemtrada®. • Expert in global market access, monetization, and scaling biotech platforms. Proven heavyweight leadership guiding $TVGN’s expansion into revenue-generating MSO/CRO operations. #Biotech #StockTwits

0 · Reply

NGCS Aug. 28 at 4:45 PM

$TVGN I have been searching CV of Management execution powerhouse 🧵 Why Team matters for the MSO/CRO shift: • Dr. Saadi (CEO): Ex-Sanofi, J&J, Genzyme. Commercialized blockbusters like Aubagio & Lemtrada ($1B+ sales). • Dr. Flomenberg (CSO): Pioneer from MSKCC / Jefferson. World-class leader in T-cell immunotherapy. • Manjit Singh (CFO): 20+ yrs leading M&A & global finance at Novartis & Sanofi. Heavyweight leaders with proven $1B+ track records executing on a micro-cap float. 📈🔥 #Tevogen #Biotech #Bullish

1 · Reply

Tevogen Bio Holdings Inc. Becomes Tevogen Inc.

Jul 13, 2026, 10:15 PM EDT - 1 month ago

Tevogen Bio Announces 2026 Annual Meeting of Stockholders

2026-06-12T21:05:21.000Z - 2 months ago

Tevogen files to sell 375,000 shares of common stock for holders

Jun 9, 2026, 3:30 PM EDT - 3 months ago

Tevogen Announces Formation of a Healthcare Services Initiative

2026-05-28T17:30:06.000Z - 3 months ago

Tevogen advances strategic acquisition initiatives

May 28, 2026, 12:30 PM EDT - 3 months ago

Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue

May 21, 2026, 12:15 PM EDT - 3 months ago

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization

2026-05-18T16:20:08.000Z - 3 months ago

Tevogen ‘working towards’ aligning long-term incentives, performance milestones

May 18, 2026, 12:15 PM EDT - 3 months ago

Letter to Shareholders from CEO Dr. Ryan Saadi

2026-05-12T18:10:14.000Z - 3 months ago

Tevogen Bio Holdings Inc trading halted, volatility trading pause

2026-05-12T18:07:55.000Z - 3 months ago

Tevogen Bio Holdings Inc trading resumes

May 12, 2026, 11:45 AM EDT - 3 months ago

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close

Apr 27, 2026, 11:50 AM EDT - 4 months ago

Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal

Mar 26, 2026, 12:45 PM EDT - 5 months ago

Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth

2026-03-25T18:25:30.000Z - 5 months ago

Tevogen regains compliance with Nasdaq minimum bid price requirement

Mar 25, 2026, 2:20 PM EDT - 5 months ago

Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mar 18, 2026, 12:22 PM EDT - 5 months ago

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)

Mar 13, 2026, 2:45 PM EDT - 5 months ago

Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization

2026-03-13T16:40:31.000Z - 5 months ago

Tevogen reports performance advancements for Tevogen.AI platform

Mar 13, 2026, 12:30 PM EDT - 5 months ago

Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure

Mar 11, 2026, 3:15 PM EDT - 6 months ago

Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform

2026-03-09T11:51:22.000Z - 6 months ago

Tevogen appoints interim leaders across core business verticals

Mar 9, 2026, 7:45 AM EDT - 6 months ago

Tevogen Names Leadership Team to Execute Diversified Growth Strategy

2026-03-06T20:45:38.000Z - 6 months ago

Tevogen CEO says ‘actively evaluating potential acquisitions’

2026-03-06T15:20:39.000Z - 6 months ago

Tevogen Bio Holdings Inc trading resumes

2026-03-06T15:15:32.000Z - 6 months ago

Tevogen Bio Holdings Inc trading halted, volatility trading pause

2026-03-06T00:51:12.000Z - 6 months ago

Tevogen Bio Holdings Inc trading halted, news pending

2026-03-05T20:00:17.000Z - 6 months ago

Tevogen signs LOI to evaluate potential acquisition of Apozeal Pharmaceutical

Mar 5, 2026, 2:50 PM EST - 6 months ago

Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical

2026-03-04T14:23:36.000Z - 6 months ago

Tevogen downgraded to Hold from Buy at D. Boral Capital

2026-03-04T13:13:07.000Z - 6 months ago

Tevogen announces 50-for-1 reverse stock split

Mar 4, 2026, 8:00 AM EST - 6 months ago

Tevogen Announces Reverse Stock Split

2026-02-27T19:25:58.000Z - 6 months ago

Tevogen signs LoI to evaluate acquisition of contract research organization

Feb 27, 2026, 2:20 PM EST - 6 months ago

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization

Feb 26, 2026, 4:22 PM EST - 6 months ago

UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus

2026-02-26T14:39:08.000Z - 6 months ago

Tevogen signs non-binding LOI to evaluate acquisition of Sciometrix

Feb 26, 2026, 9:20 AM EST - 6 months ago

Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus

2026-01-30T20:05:31.000Z - 7 months ago

Tevogen to evaluate potential one-time special cash dividend

Jan 30, 2026, 3:00 PM EST - 7 months ago

Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders

Jan 29, 2026, 2:45 PM EST - 7 months ago

Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue

2026-01-12T14:11:33.000Z - 7 months ago

Tevogen reports scientific, operational milestones achieved in 2025

Jan 12, 2026, 9:00 AM EST - 7 months ago

Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025

Dec 22, 2025, 12:40 PM EST - 8 months ago

Tevogen CEO Donates Shares to Support Education for Underprivileged Children

Dec 19, 2025, 11:10 AM EST - 8 months ago

Tevogen CEO Donates Personal Shares to Support Local Fire Department

Dec 11, 2025, 3:15 PM EST - 9 months ago

Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company's Shares of Common Stock

Dec 9, 2025, 2:20 PM EST - 9 months ago

Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine

Dec 8, 2025, 2:50 PM EST - 9 months ago

Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook

Nov 14, 2025, 2:32 PM EST - 9 months ago

Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q

2025-11-05T20:25:58.000Z - 10 months ago

Tevogen announces clinical milestone in evolution of ExacTcell platform

Nov 5, 2025, 3:20 PM EST - 10 months ago

Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID

Nov 3, 2025, 2:45 PM EST - 10 months ago

Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn

Oct 29, 2025, 12:35 PM EDT - 10 months ago

Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress

Oct 15, 2025, 3:50 PM EDT - 10 months ago

Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest

Sep 25, 2025, 8:30 AM EDT - 11 months ago

Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion

Sep 23, 2025, 8:30 AM EDT - 11 months ago

Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID

Sep 19, 2025, 3:40 PM EDT - 11 months ago

Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489's Potential Impact for 20 Million Americans

Sep 10, 2025, 11:59 AM EDT - 12 months ago

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston

Sep 9, 2025, 3:15 PM EDT - 12 months ago

Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection

Sep 8, 2025, 9:27 AM EDT - 12 months ago

Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform

Sep 4, 2025, 3:48 PM EDT - 1 year ago

Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas

Sep 3, 2025, 4:15 PM EDT - 1 year ago

Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2

Aug 27, 2025, 3:20 PM EDT - 1 year ago

Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure

Aug 26, 2025, 2:50 PM EDT - 1 year ago

Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company's Mission of Health Equity

Aug 25, 2025, 3:10 PM EDT - 1 year ago

Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions

Aug 22, 2025, 3:25 PM EDT - 1 year ago

Tevogen Recognized in BINJE's BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma

Aug 19, 2025, 3:40 PM EDT - 1 year ago

REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

Aug 19, 2025, 12:10 PM EDT - 1 year ago

Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum

Aug 18, 2025, 5:50 PM EDT - 1 year ago

Tevogen CEO Donates Personal Shares to Support Local Law Enforcement

Aug 18, 2025, 5:15 PM EDT - 1 year ago

Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery

Aug 14, 2025, 3:55 PM EDT - 1 year ago

Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected

mat70 Sep. 2 at 2:50 PM

1 · Reply

mat70 Sep. 2 at 2:49 PM

3 · Reply

robsmi63 Sep. 2 at 11:29 AM

$TVGN and yes Saadi Scam, I've nothing better to do then expose your Scam.

0 · Reply

robsmi63 Sep. 2 at 11:28 AM

0 · Reply

Nikniko55 Aug. 31 at 8:34 PM

$TVGN news?

1 · Reply

NGCS Aug. 28 at 4:56 PM

0 · Reply

NGCS Aug. 28 at 4:49 PM

0 · Reply

NGCS Aug. 28 at 4:48 PM

0 · Reply

NGCS Aug. 28 at 4:47 PM

0 · Reply

NGCS Aug. 28 at 4:45 PM

1 · Reply

NGCS Aug. 27 at 11:23 AM

$TVGN If an MSO/CRO possesses structure but—more importantly—talent (knowledgeable professionals, i.e., people), and Tevogen acquires this MSO/CRO, could TEVOGEN pay the MSO’s executives with shares to retain that talent—drawing from the 100 million shares approved in Proposal 3—while handling the "inert" portion using other payment methods I explained in a previous post (involving up to four different financing avenues)? Many thanks in advance. Best regards

1 · Reply

NGCS Aug. 27 at 11:06 AM

$TVGN Exhibits Index Page: To view the complete list of attached files and supporting documents, check the official, xhibit 3.1 (Written Consent Amendment): To read the definitive legal document regarding the corporate bylaw changes, access the Tevogen EX-3.1 Filing: https://www.sec.gov/Archives/edgar/data/1860871/000149315226040216/0001493152-26-040216-index.htm Exhibit 10.1 (Incentive Plan Contract): To audit the specific restrictive clauses governing the new employee stock options, review the Tevogen EX-10.1 Filing. https://www.sec.gov/Archives/edgar/data/1860871/000149315226040216/form8-k.htm

0 · Reply

NGCS Aug. 27 at 11:00 AM

$TVGN 1️⃣ Dilution Fear Debunked: The 100M share increase (Omnibus Plan Amendment) is legally locked for employee compensation and top-tier talent acquisition (Tevogen.AI). 2️⃣ TVGN-489 Funding Secured 3️⃣ Financial Self-Sufficiency Ahead: Management explicitly stated that closing the pending MSO/CRO acquisitions will make Tevogen completely self-sufficient. 4️⃣ SaaS Software Potential: The showcase of the Tevogen.AI final user interface (UI) confirms the algorithm is real and operational. Backed by Microsoft & Databricks, it’s ready for internal trial optimization and future high-margin commercial SaaS licensing. 🤖💻 5️⃣ Corporate Agility Activated: SEC Form 8-K officially implements the "Shareholder Action by Written Consent" amendment. ⚡️With an extremely low float (~6.4M shares out), the technical coil is tightening. Waiting for the definitive 8-K closing announcement. 📈 #BioTech #AI #LowFloat NFA, Do your own DD.

0 · Reply

NGCS Aug. 27 at 10:53 AM

$TVGN https://www.sec.gov/Archives/edgar/data/1860871/000149315226040216/form8-k.htm

0 · Reply

Somerandomnoname Aug. 24 at 9:58 PM

$TVGN I can dig all this. Voted ye on all four. I do trust these folks for the most part.

1 · Reply

NGCS Aug. 24 at 9:35 PM

$TVGN Now waiting for 8-K on SEC (and other ones)... As I answered in last post of @mat70 (thank you again for your information), IMO TVGN situation is better now than previous to videoconference. Key takeaways from today’s Shareholder Meeting 🗳️👇 1️⃣ All 4 proposals approved. The 100M share increase is strictly restricted for employee compensation & talent recruitment (Omnibus Plan). NO capital raises or market dilution intended! 🔒 2️⃣ CEO twice reiterated next clinical phase for TVGN-489 is NOT delayed by funding (capital is secure). Delay is strictly due to GMP manufacturing facility readiness 🧪🏭 3️⃣ UI for Tevogen.AI final user interface showcased. Ready for both internal optimization & future SaaS commercial licensing 🤖💻 4️⃣ While LOIs remain non-binding, management explicitly stated closing the MSO/CRO acquisitions will make Tevogen selfsuficient (revenue-generating). NFA. Best Regards.

0 · Reply

mat70 Aug. 24 at 7:27 PM

$TVGN 3/3 5- I thought the most interesting information as a response to a shareholder's question was related to TVGN 489 progress. The CEO reiterated twice that the next clinical phase was NOT being held up due to funding needs. He said funding was not a problem. The hold up is getting their manufacturing facility ready. This was a surprise twist as that contradicts their 10Q / 10K filings which says that clinical testing was waiting on additional capital. But that was clearly not the message coming from this meeting. 6- While I heard nothing on timing, what I inferred from their presentation and Q&A is that a) they expect financial self-sufficiency strictly from their healthcare services arm; pending acquisition closures, and b) progress on TVGN-489 is independent of any financing needs and strictly pending manufacturing facility readiness. I know GMP compliance is high and that's no cakewalk but I'm fairly certain they at least have the facility secured as of last summer. 3/3

3 · Reply

mat70 Aug. 24 at 7:27 PM

$TVGN 2/3 3- While they could not comment publicly on the status of any acquisition targets from their earlier LOIs, the CEO mentioned their consummation would make the company financially self sufficient. It was difficult to hear at times but I'm fairly certain there was a statement made to that affect. 4- They were explicit about the 100 million share authorization increase to be used solely for employee compensation. One member of the board mentioned something about the industry being a hotbed for talent and the need for shares at their disposal to recruit top industry talent. They explicitly mentioned that the shares would NOT be used for any other purpose other than employee compensation, i.e. not intended for use in a capital raise. 2/3

1 · Reply

mat70 Aug. 24 at 7:24 PM

$TVGN 1/3 I attended the shareholder meeting. There was no earth shattering news, but there were a couple interesting things raised. This was the summary that I got from the call (it was difficult to hear in some spots). Please correct if I got any of this wrong or missed something. Disclaimer: This is my summary from what I heard in the meeting and NOT any official transcript by the company. 1- All 4 items passed with a majority vote: Election of two Class II directors Ratification of KPMG as an independent auditor for this year Amendment to the 2024 Equity Incentive plan to increase shares authorized for awards to 100 million Amending charter to permit stockholder action by written consent. No surprises there with insiders having majority control. 2- The CEO expressed enthusiasm with progress on Tevogen AI and also showed what looked like an end user UI for what seems like a tool for both internal use and possibly a future commercial product. 1/3

1 · Reply

NGCS Aug. 24 at 5:41 PM

$TVGN There will be Questions and Answers. Are you in?

1 · Reply

NGCS Aug. 24 at 5:33 PM

$TVGN Access: https://central.virtualshareholdermeeting.com/vsm/pLogin

0 · Reply

NGCS Aug. 24 at 5:24 PM

$TVGN in 5 minutes starts voting and few days PR (I hope).

0 · Reply

Market Cap	23.41M
Revenue (ttm)	0.00
Net Income (ttm)	-26.28M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-0.65

Volume	24,207
Avg Vol	26,388
Day's Range	N/A - N/A
Shares Out	4.19M
Stochastic %K	93%
Beta	0.20
Analysts	Strong Buy
Price Target	$100.00